1-羟基-9-芴酮 | 6344-60-1

• 分子结构分类: 有机化合物 - 苯类化合物 - 芴
• 中文名称: 1-羟基-9-芴酮
• 英文名称: 1-hydroxy-9H-fluoren-9-one
• 英文别名: 1-hydroxy-9-fluorenone；1-hydroxyfluorenone；1-hydroxyfluoren-9-one；1-Hydroxy-fluoren-9-on；4-Hydroxy-9-fluorenon；1-Hydroxy-fluorenon
• CAS: 6344-60-1
• 化学式: C₁₃H₈O₂
• mdl: MFCD00044706
• 分子量: 196.205
• InChiKey: QUUNMPSDKIURJD-UHFFFAOYSA-N

物化性质

• 熔点：
  116-119 °C
• 沸点：
  293.09°C (rough estimate)
• 密度：
  1.1482 (rough estimate)
• 溶解度：
  可溶于二氯甲烷、乙酸乙酯
• 稳定性/保质期：

  与强氧化剂反应。

计算性质

• 辛醇/水分配系数(LogP)：
  3.8
• 重原子数：
  15
• 可旋转键数：
  0
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  37.3
• 氢给体数：
  1
• 氢受体数：
  2

安全信息

• 危险品标志：
  Xi
• 安全说明：
  S26,S37/39
• 危险类别码：
  R36/37/38
• 储存条件：
  密封保存，应储存在阴凉干燥的仓库中。

SDS

Name:	1-Hydroxy-9-fluorenone 99% Material Safety Data Sheet
Synonym:	Non
CAS:	6344-60-1

Section 1 - Chemical Product MSDS Name:1-Hydroxy-9-fluorenone 99% Material Safety Data Sheet
Synonym:Non

---

Section 2 - COMPOSITION, INFORMATION ON INGREDIENTS

CAS#	Chemical Name	content	EINECS#
6344-60-1	1-Hydroxy-9-fluorenone, 99%	99%	228-746-4

Hazard Symbols: XI
Risk Phrases: 36/37/38

---

Section 3 - HAZARDS IDENTIFICATION
EMERGENCY OVERVIEW
Irritating to eyes, respiratory system and skin.The toxicological properties of this material have not been fully investigated.
Potential Health Effects
Eye:
Causes eye irritation.
Skin:
Causes skin irritation.
Ingestion:
May cause irritation of the digestive tract. The toxicological properties of this substance have not been fully investigated.
Inhalation:
Causes respiratory tract irritation. The toxicological properties of this substance have not been fully investigated.
Chronic:
No information found.

---

Section 4 - FIRST AID MEASURES
Eyes: Flush eyes with plenty of water for at least 15 minutes, occasionally lifting the upper and lower eyelids. Get medical aid immediately.
Skin:
Get medical aid. Flush skin with plenty of water for at least 15 minutes while removing contaminated clothing and shoes.
Ingestion:
If victim is conscious and alert, give 2-4 cupfuls of milk or water.
Get medical aid immediately.
Inhalation:
Get medical aid immediately. Remove from exposure and move to fresh air immediately. If not breathing, give artificial respiration. If breathing is difficult, give oxygen.
Notes to Physician:

---

Section 5 - FIRE FIGHTING MEASURES
General Information:
As in any fire, wear a self-contained breathing apparatus in pressure-demand, MSHA/NIOSH (approved or equivalent), and full protective gear.
Extinguishing Media:
Use foam, dry chemical, or carbon dioxide.

---

Section 6 - ACCIDENTAL RELEASE MEASURES
General Information: Use proper personal protective equipment as indicated in Section 8.
Spills/Leaks:
Vacuum or sweep up material and place into a suitable disposal container.

---

Section 7 - HANDLING and STORAGE
Handling:
Wash thoroughly after handling. Use with adequate ventilation. Avoid contact with skin and eyes. Avoid ingestion and inhalation.
Storage:
Store in a cool, dry place. Store in a tightly closed container.

---

Section 8 - EXPOSURE CONTROLS, PERSONAL PROTECTION
Engineering Controls:
Facilities storing or utilizing this material should be equipped with an eyewash facility and a safety shower. Use process enclosure, local exhaust ventilation, or other engineering controls to control airborne levels.
Exposure Limits CAS# 6344-60-1: Personal Protective Equipment Eyes: Wear appropriate protective eyeglasses or chemical safety goggles as described by OSHA's eye and face protection regulations in 29 CFR 1910.133 or European Standard EN166.
Skin:
Wear appropriate protective gloves to prevent skin exposure.
Clothing:
Wear appropriate protective clothing to prevent skin exposure.
Respirators:
Follow the OSHA respirator regulations found in 29 CFR 1910.134 or European Standard EN 149. Use a NIOSH/MSHA or European Standard EN 149 approved respirator if exposure limits are exceeded or if irritation or other symptoms are experienced.

---

Section 9 - PHYSICAL AND CHEMICAL PROPERTIES

Physical State: Solid
Color: yellow
Odor: Not available.
pH: Not available.
Vapor Pressure: Not available.
Viscosity: Not available.
Boiling Point: @ 760.00mm Hg
Freezing/Melting Point: 117 - 118 deg C
Autoignition Temperature: Not available.
Flash Point: Not available.
Explosion Limits, lower: Not available.
Explosion Limits, upper: Not available.
Decomposition Temperature:
Solubility in water:
Specific Gravity/Density:
Molecular Formula: C13H8O2
Molecular Weight: 196.20

---

Section 10 - STABILITY AND REACTIVITY
Chemical Stability:
Stable under normal temperatures and pressures.
Conditions to Avoid:
None reported.
Incompatibilities with Other Materials:
Strong oxidizing agents.
Hazardous Decomposition Products:
Carbon monoxide, carbon dioxide.
Hazardous Polymerization: Has not been reported.

---

Section 11 - TOXICOLOGICAL INFORMATION
RTECS#:
CAS# 6344-60-1 unlisted.
LD50/LC50:
Not available.
Carcinogenicity:
1-Hydroxy-9-fluorenone, 99% - Not listed by ACGIH, IARC, or NTP.

---

Section 12 - ECOLOGICAL INFORMATION

---

Section 13 - DISPOSAL CONSIDERATIONS
Dispose of in a manner consistent with federal, state, and local regulations.

---

Section 14 - TRANSPORT INFORMATION

IATA
Not regulated as a hazardous material.
IMO
Not regulated as a hazardous material.
RID/ADR
Not regulated as a hazardous material.

---

Section 15 - REGULATORY INFORMATION

European/International Regulations
European Labeling in Accordance with EC Directives
Hazard Symbols: XI
Risk Phrases:
R 36/37/38 Irritating to eyes, respiratory system
and skin.
Safety Phrases:
S 26 In case of contact with eyes, rinse immediately
with plenty of water and seek medical advice.
S 37/39 Wear suitable gloves and eye/face
protection.
WGK (Water Danger/Protection)
CAS# 6344-60-1: No information available.
Canada
None of the chemicals in this product are listed on the DSL/NDSL list.
CAS# 6344-60-1 is not listed on Canada's Ingredient Disclosure List.
US FEDERAL
TSCA
CAS# 6344-60-1 is not listed on the TSCA inventory.
It is for research and development use only.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  1-羟基-9-芴酮 在 sodium tetrahydroborate 作用下， 以 乙醇 为溶剂， 反应 3.0h， 以100%的产率得到1-hydroxy-9-fluorenol
  参考文献：
  名称：

  1-和2-羟基-9-芴醇在水溶液中光解的对比行为

  摘要：

  在水溶液中研究了 1-和 2-羟基-9-芴醇 4-6 的光解。所有这些 9-芴醇均可在 1:1 H 2O-CH3OH 中有效地光解，以高化学和量子产率得到相应的甲基醚产物。已知母体 9-芴醇 (2 , R=H ) 的光解作用是通过非常短命的、形式上为基态的抗芳族 9-芴基阳离子 ( 1, R = H ) 进行的，而 1- 羟基- 9-芴醇 (4) 通过寿命更长 (≈5-10 s) 的芴基醌甲基化物 9 进行，其可通过 (4+2) 环加成反应被乙基乙烯基醚捕获，得到色满衍生物。有趣的是，2-羟基-9-芴醇（5）通过一个非常短寿命的中间体进行光解，其寿命与对 9-芴基阳离子（1，R = H）观察到的相似，尽管该化合物可以得到相应的芴基醌甲基化物中间体。该研究表明，当存在芳基羟基时，可以显着改变这些类型化合物的光解作用机制。

  DOI：

  10.1139/cjc-77-5-6-868
• 作为产物：
  描述：

  1-氨基-9-芴酮 在 硫酸 、 sodium nitrite 作用下， 反应 2.25h， 以70%的产率得到1-羟基-9-芴酮
  参考文献：
  名称：

  用电子调谐的重氮芴类似物模拟重氮苯并[b]芴天然产物的生物活性。

  摘要：

  在适当的电子调制下，简单的重氮芴类似物在基于硫醇的还原条件下概括了凯那霉素D的DNA裂解活性。在这些还原条件下实现DNA裂解是抗癌活性的关键，因为最具活性的化合物1-甲氧基重氮芴可抑制HeLa细胞的增殖。

  DOI：

  10.1016/j.bmcl.2006.07.024

文献信息

• Directed ortho Metalation (DoM)-Linked Corriu–Kumada, Negishi, and Suzuki–Miyaura Cross-Coupling Protocols: A Comparative Study
  作者：Victor Snieckus、Claude Quesnelle

  DOI：10.1055/s-0037-1611053

  日期：2018.11

  the DoM strategy lends itself to the regioselective construction of diversely substituted aromatics and heteroaromatics. A systematic study of the widely used, titled name reaction transition-metal-catalyzed cross-coupling reactions with attention to context with the directed ortho metalation (DoM) is reported. In general, the Suzuki–Miyaura and Negishi protocols show greater scope and better yields

  致力于斯科特丹麦：至此，我们（以及缺席的KB ）正在庆祝您的创造力和成就。 发布时间作为的一部分奉献给斯科特E.丹麦在他65之际特别节日的生日。 抽象的 报告了对广泛使用的标题反应过渡金属催化的交叉偶联反应的系统研究，并着眼于定向原金属化（D o M）。通常，Suzuki-Miyaura和Negishi方案比Corriu-Kumada方案具有更大的范围和更高的产量，尽管后者定性地以最快的速度进行，但功能基团的耐受性较低。据证明，Negishi工艺可用于具有亲核试剂和碱敏感功能的底物，其效率可与Suzuki-Miyaura反应媲美。这些交叉偶联反应与D o M策略的联系使其适用于不同取代的芳族化合物和杂芳族化合物的区域选择性结构。 报告了对广泛使用的标题反应过渡金属催化的交叉偶联反应的系统研究，并着眼于定向原金属化（D o M）。通常，Suzuki-Miyaura和Negishi方案比Cor
• Gold(I)-Catalyzed Intramolecular Hydroarylation of Phenol-Derived Propiolates and Certain Related Ethers as a Route to Selectively Functionalized Coumarins and 2<i>H</i>-Chromenes
  作者：Aymeric Cervi、Yen Vo、Christina L. L. Chai、Martin G. Banwell、Ping Lan、Anthony C. Willis

  DOI：10.1021/acs.joc.0c02011

  日期：2021.1.1

  Methods are reported for the efficient assembly of a series of phenol-derived propiolates, including the parent system 56, and their Au(I)-catalyzed cyclization (intramolecular hydroarylation) to give the corresponding coumarins (e.g., 1). Simple syntheses of natural products such as ayapin (144) and scoparone (145) have been realized by such means, and the first of these subject to single-crystal

  报道了有效组装一系列由苯酚衍生的丙酸酯的方法，包括母体系统56，以及它们的Au（I）催化的环化（分子内氢芳基化），得到相应的香豆素（例如1）。通过这样的方法已经实现了天然产物例如ayapin（144）和scoparone（145）的简单合成，并且首先对它们进行单晶X射线分析。描述了一种用于将诸如156的炔丙基醚转化为天然存在的少年激素生物合成抑制剂的异构体2 H-苯并二茂烯I（159）的方法。
• Synthesis of Functionalized Biaryls Based on a Heck Cross-Coupling-[3+3] Cyclization Strategy
  作者：Peter Langer、Gerson Mroß、Helmut Reinke

  DOI：10.1055/s-2008-1072654

  日期：——

  6-Arylsalicylates were regioselectively prepared by formal [3+3] cyclization of 1,3-bis(silyloxy)-1,3-butadienes with 1-aryl-3-ethoxyprop-2-en-1-ones which are available by Heck reaction of benzoyl chlorides with ethylvinyl ether. In this context, the first [3+3] cyclizations of brominated substrates are reported.

  通过1,3-双(硅氧基)-1,3-丁二烯与1-芳基-3-乙氧基丙-2-烯-1-酮的正式[3+3]环化反应，区域选择性地合成了6-芳基水杨酸酯。而1-芳基-3-乙氧基丙-2-烯-1-酮则可通过苯甲酰氯与乙基乙烯基醚的Heck反应获得。在这样的背景下，首次报道了溴化底物的[3+3]环化反应。
• Synthesis of Functionalized Salicylates by Formal [3+3] Cyclocondensation of 1,3-Bis(silyloxy)buta-1,3-dienes with 3-Alkoxy-2-en-1-ones
  作者：Peter Langer、Gerson Mroß、Simone Ladzik、Helmut Reinke、Anke Spannenberg、Christine Fischer

  DOI：10.1055/s-0029-1216814

  日期：2009.7

  The formal [3+3] cyclization of 1,3-bis(silyloxy)buta-1,3-dienes with 1-aryl-3-ethoxyprop-2-en-1-ones, available by Heck reaction of benzoyl chlorides with ethyl vinyl ether, afforded a variety of 6-arylsalicylates. The reaction of the products with concentrated sulfuric acid resulted in the formation of fluorenones. 6-Alkylsalicylates were prepared by cyclization of 1,3-bis(silyl­oxy)buta-1,3-dienes

  1,3-双（甲硅烷氧基）丁1,3-二烯与1-芳基-3-乙氧基丙-2-烯-1-酮的正式[3 + 3]环化，可通过苯甲酰氯与乙基的Heck反应获得乙烯基醚，得到各种6-芳基水杨酸酯。产物与浓硫酸的反应导致芴酮的形成。通过将1，3-双（甲硅烷氧基）丁1，3-二烯与脂族烯酮环合制备6-烷基水杨酸酯。 芳烃-环化-钯-区域选择性-甲硅烷基烯醇醚
• Substituted 2- (S) -hydroxy-3- (piperidin-4-yl-methylamino) -propyl ethers and substituted 2-aryl-2- (R) - hydroxy-1- (piperidin-4-yl-methyl) -ethylamine beta-3 adrenergic receptor agonists
  申请人：American Home Products Corporation

  公开号：US20020037907A1

  公开（公告）日：2002-03-28

  This invention provides compounds of Formula I having the structure 1 wherein A, B, Z, R and R 1 are as defined hereinbefore, or a pharmaceutically acceptable salt thereof, which are useful in treating or inhibiting metabolic disorders related to insulin resistance or hyperglycemia (typically associated with obesity or glucose intolerance), atherosclerosis, gastrointestinal disorders, neurogenetic inflammation, glaucoma, ocular hypertension and frequent urination; and are particularly useful in the treatment or inhibition of type II diabetes.

  这项发明提供了具有结构式1的化合物，其中A、B、Z、R和R1如前文所定义，或其药学上可接受的盐，用于治疗或抑制与胰岛素抵抗或高血糖相关的代谢紊乱（通常与肥胖或葡萄糖不耐受有关）、动脉粥样硬化、胃肠道疾病、神经炎症、青光眼、眼压增高和频繁排尿；特别适用于治疗或抑制2型糖尿病。

表征谱图